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OBJECTIVES This study was designed to assess effects of mitral valve annuloplasty (MVA) on mortality in
patients with mitral regurgitation (MR) and left ventricular (LV) systolic dysfunction.
BACKGROUND Mitral valve annuloplasty improves hemodynamics and symptoms in these patients, but
effects on long-term mortality are not well established.
METHODS We retrospectively analyzed consecutive patients with significant MR and LV systolic
dysfunction on echocardiography between 1995 and 2002. Cox regression analysis, including
MVA as a time-dependent covariate and propensity scoring to adjust for differing probabil-
ities of undergoing MVA, was used to identify predictors of death, LV assist device
implantation, or United Network for Organ Sharing-1 heart transplantation.
RESULTS Of 682 patients identified, 419 were deemed surgical candidates; 126 underwent MVA.
Propensity score derivation identified age, ejection fraction, and LV dimension to be
associated with undergoing MVA. End points were reached in 120 (41%) non-MVA and 62
(49%) MVA patients. Increased risk of end point was associated with coronary artery disease
(hazard ratio [HR] 1.80, 95% confidence interval [CI] 1.30 to 2.49), blood urea nitrogen (HR
1.01, 95% CI 1.005 to 1.02), cancer (HR 2.77, 95% CI 1.45 to 5.30), and digoxin (HR 1.66,
95% CI 1.15 to 2.39). Reduced risk was associated with angiotensin-converting enzyme
inhibitors (HR 0.65, 95% CI 0.44 to 0.95), beta-blockers (HR 0.59, 95% CI 0.42 to 0.83),
mean arterial pressure (HR 0.98, 95% CI 0.97 to 0.99), and serum sodium (HR 0.93, 95%
CI 0.90 to 0.96). Mitral valve annuloplasty did not predict clinical outcome.
CONCLUSIONS In this analysis, there is no clearly demonstrable mortality benefit conferred by MVA for
significant MR with severe LV dysfunction. A prospective randomized control trial is
warranted for further study of mortality with MVA in this population. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.0732005;45:381–7) © 2005 by the American College of Cardiology Foundation
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watients with heart failure (HF) due to left ventricular (LV)
ystolic dysfunction frequently develop mitral regurgitation
MR) because of unfavorable alterations in LV geometry
esulting in deformation of the normal mitral valve appara-
us and dilation of the ventricular chamber, which in turn
ead to incomplete closure of the mitral valve leaflets (1–3).
See page 388
he presence of MR in the setting of LV dysfunction is
ssociated with increased mortality (4–6). Previously, sur-
ical treatment of MR was avoided in patients with severe
V systolic dysfunction owing to concern about operative
isk and perioperative complications in patients. More
ecently, with improvements in surgical techniques and
ncreased knowledge of the benefit of preserving the com-
From the *Division of Cardiology, Department of Internal Medicine, †Section of
ardiac Surgery, Department of Surgery; and ‡Center for Statistical Consultation
nd Research, University of Michigan Health Systems, Ann Arbor, Michigan.e
Manuscript received February 10, 2004; revised manuscript received September 17,
004, accepted September 21, 2004.lete mitral valve apparatus for long-term preservation of
V function (7,8), surgical mitral valve annuloplasty
MVA) for MR in the setting of LV dysfunction has
ecome a more popular treatment option. Several published
eries have shown that postoperative mortality in this
opulation is low, HF symptoms are ameliorated, ventric-
lar size and ejection fraction improve, and intermediate-
erm outcomes are favorable (9–12). What effect MVA has
n long-term outcomes, specifically mortality, in patients
ith HF attributable to LV dysfunction is not well estab-
ished. To assess the effect of MVA on mortality in this
atient population, we retrospectively analyzed a consecu-
ive series of patients with severe MR and LV systolic
ysfunction who received care in the University of Michigan
ealth System.
ETHODS
his study was approved by the University of Michigan
nstitutional Review Board before data collection. Patients
ere included in the study population if they had undergonechocardiography in the adult echocardiography laboratory
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hey were found to have a LV ejection fraction 30%
severe impairment) and had at least moderate to severe
R. Patients were excluded from this analysis if they had
ndergone previous mitral valve surgery, had a history of
omplex congenital heart disease, received a cardiac support
evice as part of a clinical trial in conjunction with MVA,
ad mitral valve replacement rather than MVA, or had
oncomitant aortic valve surgery with MVA (patients who
nderwent concurrent tricuspid valve surgery were in-
luded). The study population represents a consecutive
eries of patients meeting these criteria. All patients under-
oing MVA in this study did so in the University of
ichigan Health System through the Section of Cardiac
urgery. The surgeries took place as part of clinical care and
ere performed by one of five different staff surgeons, with
he vast majority performed by one of two surgeons (S.F.B.
5%, F.D.P. 15%). The surgical technique used has been
reviously described (10).
Patients’ clinical characteristics at the time of echocardi-
graphy were recorded with respect to underlying cause of
ardiomyopathy, medical comorbidities, physical examina-
ion findings, serum chemistries, medications, and findings
n electrocardiography. Records were also reviewed inde-
endently by two cardiologists (T.K. and A.W.) and deter-
ination was made whether the patients would have a
ontraindication to referral for MVA. Determinations of
urgical candidacy were performed in a manner blinded to
he subsequent surgical decision. Conditions considered to
e contraindications to surgery included metastatic cancer or
ny active diagnosis of cancer within five years preceding the
ndex echocardiogram, recent stroke (within six months),
evere chronic obstructive pulmonary disease, inoperable
oronary disease, renal failure (serum creatinine 3.5 mg/
l, although hemodialysis was not considered a criterion for
on-candidacy), inotrope dependency at the time of the
ndex echocardiogram, arrhythmia (life-threatening, refrac-
ory to medical therapy necessitating urgent ablation pro-
edure or mechanical support), peripheral vascular disease
accompanied by rest pain or ischemic ulcers requiring
urgery or wound care strategies), other comorbidities likely
o limit the survival of the patient, moribund state (immi-
ently about to die from severe or multiple medical prob-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
HF  heart failure
HR  hazard ratio
LV  left ventricular
MR  mitral regurgitation
MVA  mitral valve annuloplasty
OR  odds ratio
UNOS  United Network for Organ Sharingems), and urgent transplant evaluation (defined as patient fieing listed United Network for Organ Sharing [UNOS]
tatus 1A or 1B within 30 days after index echocardiogram).
ll echocardiograms were performed transthoracically, us-
ng standard windows. Quantitative analysis was performed
y an experienced echocardiographer. Mitral regurgitation
as assessed using color-flow Doppler as mild, mild-
oderate, moderate, moderate-severe, or severe (6). Final
uantitative and qualitative interpretation of echocardio-
raphic and Doppler imaging was performed by an attend-
ng echocardiographer blinded to the subsequent clinical
utcome of the patient and as part of usual care.
tatistical analysis. Statistical analyses were performed
sing SPSS Version 10.0 statistical software (SPSS Inc.,
hicago, Illinois). Graphical display of event-free survival
as produced using R Version 1.9.1 (R Foundation for
tatistical Computing, Vienna, Austria). Results were con-
idered to be statistically significant where p  0.05.
nalyses for three patient groups were performed: 1) pa-
ients determined to be non-candidates for MVA, 2) can-
idates for MVA who did not undergo MVA, and 3)
andidates for MVA who underwent MVA. Baseline char-
cteristics were determined for each patient group. Chi-
quare and Wilcoxon rank-sum tests were used to compare
ategorical and continuous variables, respectively. The pri-
ary clinical end point of interest was death, LV assist
evice implantation, or transplantation from UNOS status
. Patients transplanted from UNOS status 2 were censored
t the time of transplantation.
A propensity score was derived, reflecting the probability
hat a patient would undergo MVA. This was accomplished
y performing a multivariable logistic regression analysis
sing MVA as the dependent outcome variable and entering
ll demographics, physical examination findings, electrocar-
iography and echocardiography measurements, and med-
cations that clinically would likely affect the probability of
ndergoing MVA. These variables included age, male
ender, whether hospitalized at time of index echocardio-
ram, diabetes, atrial fibrillation, chronic obstructive pul-
onary disease, cancer, prior coronary bypass surgery,
troke, blood urea nitrogen, beta-blocker use, angiotensin-
onverting enzyme (ACE) inhibitor use, spironolactone use,
igoxin use, inotrope use, heart rate, mean arterial pressure,
resence of implantable cardioverter-defibrillator, LV ejec-
ion fraction, LV diastolic dimension, severity of tricuspid
egurgitation, paced rhythm, and QRS interval. Stepwise
ackward elimination was employed and the resultant in-
ependent predictors of MVA were then used to calculate
he probability of undergoing MVA (propensity score).
nly patients felt to be candidates for MVA were included
n the propensity score derivation and subsequent survival
nalysis.
A Cox proportional-hazards model to analyze the effect
f MVA on event-free survival was used, treating MVA as
time-dependent covariate. Variables entered into the
nitial model included demographics, physical examination
ndings, electrocardiography and echocardiography mea-
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February 1, 2005:381–7 Mitral Valve Annuloplasty for MR and LV Dysfunctionurements, and medications. With the propensity score
orced into the model, the remaining variables were selected
sing a backward elimination method. All analyses were
erformed on the entire dataset and then repeated on the
ohort of patients without coronary disease (nonischemic
ohort). Coronary artery disease was defined as presence of
ny coronary stenosis70% diameter, history of myocardial
nfarction, or history of revascularization.
The graphical display of event-free survival based on the
ime-dependent covariate of mitral valve annuloplasty was
erformed according to the method described by Venables
nd Ripley (13). Using this method, the survival time for the
edically treated patients was taken from the time of
chocardiogram to the time of event or last follow-up. Each
VA-treated patient was treated as two records. The first
ecord created for the MVA patients represented the pre-
VA treated survival time from the time of the echocar-
iogram to the time of the MVA. For these records, the
VA coding variable indicated non-MVA and the status
ariable indicated survival free of event. The second record
reated for the MVA patients represented the post-MVA
reated survival time from the time of MVA to the time of
vent or last follow-up. In these records, the MVA coding
ariable indicated MVA, and the status variable was based
n the individual patient’s event status. The plot of event-
ree survival based on MVA as a time-dependent covariate
as adjusted for the independent predictors identified in the
ox proportional hazards analysis, setting each covariate at
he average value for the patient population.
ESULTS
f the 682 total patients in the study, 419 were felt to be
andidates for MVA, and 126 of these underwent MVA.
able 1. Baseline Characteristics
Candidate Had MVA
(n  126)
ale 80 (63%)
ge (yrs) 65.5  9.6
ospitalized at time of echocardiogram 61 (48%)
onths followed before echocardiogram 7.2  14.1
oronary artery disease 89 (71%)
iabetes 33 (26%)
hronic obstructive pulmonary disease 12 (10%)
troke 4 (3%)
ecent myocardial infarction 10 (8%)
mplantable cardioverter-defibrillator 23 (18%)
ancer 4 (3%)
rior coronary bypass surgery 34 (27%)
ean arterial pressure (mm Hg) 85  14
eart rate (beats/min) 80  16
odium (mmol/l) 138  4
lood urea nitrogen (mg/dl) 29  20
reatinine (mg/dl) 1.4  0.9
trial fibrillation 33 (26%)
aced 11 (9%)
RS interval (ms) 131  37Had MVA vs. not candidate; †Candidate/had MVA vs. candidate/no MVA.
MVA  mitral valve annuloplasty; NS  not significant (p  0.05).ecisions for candidacy were concordant between the two
eviews on 675 of 682 subjects (99%). Survival analysis
epeated with either reviewer’s candidate decisions did not
esult in different findings in the study. The reasons for
atients determined not to be candidates for MVA included
ardiogenic shock (n 34, 12.9%), metastatic/recent cancer
n  31, 11.8%), renal failure (n  30, 11.4%), significant
alvular lesion other than MR (n  30, 11.4%), felt to be
oo frail to undergo MVA after evaluation by cardiac
urgeon or cardiologist (n  21, 8.0%), severe chronic
bstructive pulmonary disease (n  13, 4.9%), infection (n
13, 4.9%), delirium or dementia (n  13, 4.9%), acute
yocardial infarction (n  12, 4.6%), intracranial hemor-
hage or recent stroke (n  12, 4.6%), urgent transplant
valuation (n  11, 4.2%), cardiac arrest (n  10, 3.8%),
noperable coronary disease (n  10, 3.8%), peripheral
ascular disease (n  8, 3.0%), or other reasons (n  26,
.9%) (many patients had more than one reason). Other
easons included primarily the coexistence of conditions that
ncreased risk of cardiac surgery (such as dehisced aortic root
eplacement, pulmonary hypertension, and ventricular sep-
al defect), or medical conditions that limited survival
ndependent of surgery (such as giant cell myocarditis,
nd-stage liver disease, pulmonary sarcoid, and systemic
upus erythematosus). Baseline characteristics are shown in
able 1. Patients who did not have MVA were as a group
ignificantly younger, were less likely to have coronary artery
isease, were more likely to have an implantable
ardioverter-defibrillator, and had higher heart rate than
atients who did have MVA.
Echocardiography and medication data are shown in
ables 2 and 3, respectively. Compared with the patients
ho underwent MVA, patients who did not have MVA had
t Candidate
n  263) p*
Candidate but No MVA
(n  293) p†
52 (58%) NS 171 (58%) NS
5.4  15.1 NS 60.9  15.3 0.006
86 (71%) 0.0001 142 (48%) NS
1.4  18.4 NS 13.2  19.1 0.03
67 (64%) NS 150 (51%) 0.0002
72 (27%) NS 81 (28%) NS
47 (18%) 0.03 28 (10%) NS
22 (8%) NS 17 (6%) NS
46 (17%) 0.01 11 (4%) NS
60 (23%) NS 88 (30%) 0.01
24 (9%) 0.03 9 (3%) NS
74 (28%) NS 70 (24%) NS
83  17 NS 86  16 NS
89  20 0.0001 85  19 0.03
36  5 0.0002 138  4 NS
39  24 0.0001 28  17 NS
2.0  1.7 0.0001 1.5  1.2 NS
80 (30%) NS 68 (23%) NS
38 (14%) NS 42 (14%) NS
26  36 NS 128  36 NSNo
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ion. The non-MVA group was more likely to be treated
ith spironolactone when compared to the MVA group.
ther medical treatments, such as ACE inhibitors, beta-
lockers, digoxin, and intravenous inotropes, did not differ
ignificantly between the MVA and non-MVA groups.
The variables that were significant in the final multivari-
ble logistic regression model defining the propensity scor-
ng included age (per 1 year older, odds ratio [OR] 1.03,
5% confidence interval [CI] 1.008 to 1.05), LV ejection
raction (per 1% point increase, OR 1.09, 95% CI 1.05 to
.13), and LV diastolic dimension (per 1 mm increase, OR
.04, 95% CI 1.01 to 1.07). These variables indicate clinical
haracteristics associated with significantly increased base-
ine probability to undergo MVA: older age, higher LV
jection fraction, and larger LV dimension. The propensity
cores for the non-MVA patients and MVA patients were
.29  0.13 and 0.37  0.13, respectively (p  0.0001).
hese results are consistent with the differences seen in
aseline characteristics between the MVA and non-MVA
roups.
A total of 177 (67%) patients determined not to be
andidates for MVA died during the follow-up period. Of
hose determined to be candidates for surgery, 112 patients
38%) who did not have MVA died versus 61 (48%) of those
ho had MVA (p  NS). Thirty-day mortality for the
VA group (postsurgical mortality) was 4.8% (6 patients).
he combined end point of death, implantation of a LV
ssist device, or transplantation from UNOS status 1 was
able 2. Echocardiogram Characteristics
Had MVA
(n  126)
Not
(n
eft atrial size (mm) 51  7 4
eft ventricular diastolic diameter (mm) 65  8 6
eft ventricular systolic diameter (mm) 54  12 5
eft ventricular ejection fraction (%) 23  7 2
ricuspid regurgitation
None–mild 67 (53%) 9
Mild/moderate–moderate 38 (30%) 9
Moderate/severe–severe 21 (17%) 8
Had MVA vs. not candidate; †candidate/had MVA vs. candidate/no MVA.
MVA  mitral valve annuloplasty; NS  not significant (p  0.05).
Table 3. Medications
Had MVA
(n  126)
Not Ca
(n 
ACE inhibitor 98 (78%) 170 (
Beta-blocker 41 (33%) 94 (
Digoxin 81 (64%) 146 (
Loop diuretic 99 (79%) 202 (
Spironolactone 19 (15%) 45 (
Nitrate 33 (26%) 77 (
Hydralazine 5 (4%) 22 (
Aspirin 73 (58%) 132 (
Calcium-channel blocker 15 (12%) 24 (
Inotropes 6 (5%) 40 (*Had MVA vs. not candidate; †candidate/had MVA vs. candidate
ACE  angiotensin-converting enzyme; MVA  mitral valveeached by 62 (49%) patients who underwent MVA versus
20 (41%) patients who did not have MVA (p  NS).
Results of multivariable Cox regression analysis are
hown in Table 4. Factors associated with increased risk of
he combined outcome include presence of coronary artery
isease (hazard ratio [HR] 1.80, 95% CI 1.30 to 2.49),
lood urea nitrogen (per 1 mg/dl increase, HR 1.01, 95% CI
.005 to 1.02), history of cancer (HR 2.77, 95% CI 1.45 to
.30), and digoxin use (HR 1.66, 95% CI 1.15 to 2.39).
educed risk of the combined outcome was associated with
CE inhibitor use (HR 0.65, 95% CI 0.44 to 0.95),
eta-blocker use (HR 0.59, 95% CI 0.42 to 0.83), higher
ean arterial pressure (per 1 mm Hg increase, HR 0.98,
5% CI 0.97 to 0.99), and higher serum sodium (per 1
mol/l increase, HR 0.93, 95% CI 0.90 to 0.96). Whether
he propensity score was allowed to be removed or was
orced into the model did not influence the final prediction
odel significantly. Mitral valve annuloplasty status, treated
s a time-dependent covariate, was not an independent
redictor of clinical outcome in this analysis. The event-free
urvival based on MVA as a time-dependent covariate,
djusted for the independent predictors identified in the
ox proportional hazards analysis, is shown in Figure 1.
After exclusion of subjects with coronary artery disease,
he study sample consisted of 276 patients: 96 (35%)
atients were determined not to be candidates for surgery,
nd of the remaining 180 who were believed to be surgical
andidates, 37 (21%) underwent MVA. Comparisons of the
aseline characteristics of the MVA and the non-MVA
idate
3) p*
Candidate but No MVA
(n  293) p†
0.001 50  8 NS
0 0.001 65  10 NS
2 NS 57  12 0.04
0.0003 19  7 0.0001
0.0008 NS
) 121 (41%)
) 99 (34%)
) 73 (25%)
te
p*
Candidate but No MVA
(n  293) p†
0.009 235 (80%) NS
NS 125 (43%) NS
NS 190 (65%) NS
NS 244 (83%) NS
NS 81 (28%) 0.006
NS 57 (19%) NS
NS 9 (3%) NS
NS 150 (51%) NS
NS 25 (9%) NS
0.003 9 (3%) NSCand
 26
8  8
2  1
3  1
0  7
1 (35%
1 (35%
1 (31%ndida
263)
65%)
36%)
56%)
77%)
17%)
29%)
8%)
50%)
9%)
15%)/no MVA.
annuloplasty; NS  not significant (p  0.05).
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ataset described earlier. The MVA and non-MVA subjects
iffered with respect to age (63.4  11.0 years vs. 54.6 
6.4 years, p  0.002), heart rate (81  16 beats/min vs. 90
21 beats/min, p 0.02), serum sodium (139 5 mmol/l
s. 137 4 mmol/l, p 0.006), LV ejection fraction (21
% vs. 17  7%, p  0.0001), and spironolactone use (19%
s. 36%, p  0.04). The derived propensity score for the
o-coronary-disease cohort consisted of the same variables
efined by the all-inclusive cohort: age, LV ejection frac-
ion, and LV diastolic dimension. The Cox proportional
azards analysis, treating MVA as a time-dependent covari-
te, selected ACE inhibitor use (HR 0.40, 95% CI 0.21 to
.76, p  0.005), digoxin use (HR 2.86, 95% CI 1.25 to
.58, p  0.01), serum sodium (per 1 mmol/l increase, HR
.92, 95% CI 0.87 to 0.97, p  0.001), and QRS interval
per 1 ms increase, HR 1.01, 95% CI 1.00 to 1.02, p 
.04), but not the time-dependent covariate, as independent
redictors of event-free survival. The event-free survival
ased on MVA as a time-dependent covariate for the
atients without coronary artery disease, adjusted for the
ndependent predictors identified in the Cox proportional
azards analysis, is shown in Figure 2.
ISCUSSION
itral valve repair, or annuloplasty, is the preferred surgical
reatment of functional mitral regurgitation compared to
itral replacement (14,15). Whereas previous studies have
emonstrated that MVA is associated with low surgical
ortality and leads to improvement of heart failure symp-
oms in patients with MR and severe LV systolic dysfunc-
ion, studies comparing the outcomes of these patients with
atients treated medically are not available (9,11,12,16,17).
revious studies of MVA in the setting of ischemic MR
ave shown that it does not appear to be associated with
mproved survival compared to coronary artery bypass graft-
ng surgery alone in patients with relatively preserved
ystolic function (18). Our study does not demonstrate a
Table 4. Results of Multivariable Cox Regressi
Combined End Point of Death, Ventricular A
Organ Sharing-1 Transplantation
ACE inhibitor
Beta-blocker
Blood urea nitrogen (per 1 mg/dl increase)
Cancer
Coronary artery disease
Digoxin
Mean arterial pressure (per 1 mm Hg increase)
Sodium (per 1 mmol/l increase)
Variables removed: mitral valve annuloplasty (time-dependen
paced rhythm, hospitalized at time of index echocardiogram,
obstructive lung disease, spironolactone, heart rate, implantab
of stroke, QRS interval, prior coronary bypass surgery, LV d
ACE  angiotensin-converting enzyme; CI  confide
abbreviations as in Table 3.urvival advantage conferred by MVA compared to medical
F
gherapy in patients with mitral regurgitation and LV systolic
ysfunction. After excluding patients who were not surgical
andidates and controlling for potentially confounding clin-
cal factors, the event-free survival was not significantly
ifferent between medically and surgically treated patients.
The similar outcomes between the two groups cannot be
eadily explained by intergroup differences, as baseline
haracteristics and medical therapy of candidate patients
ho underwent MVA versus those who did not were largely
imilar. There were no differences in the use of ACE
nhibitors, beta-blockers, digoxin, or loop diuretics. It is
ikely that the higher use of spironolactone in the non-
VA group is related to care practice differences between
niversity of Michigan Health System cardiologists and
ardiologists referring patients for surgical intervention.
There were some differences in baseline characteristics
etween the two groups that warrant discussion. Most of
hese differences, including higher heart rate and lower LV
jection fraction, indicate poorer prognosis for the non-
VA group, whereas two—younger age and less coronary
odel Using Backward Stepwise Selection, for
Device Implantation, or United Network for
R (95% CI) Chi-Square p
5 (0.44, 0.95) 4.86 0.03
9 (0.42, 0.83) 9.08 0.003
1 (1.005, 1.02) 11.00 0.0009
7 (1.45, 5.30) 9.43 0.002
0 (1.30, 2.49) 12.37 0.0004
6 (1.15, 2.39) 7.26 0.007
8 (0.97, 0.99) 11.87 0.0006
3 (0.90, 0.96) 17.47 0.0001
iate), MVA propensity score, diabetes, age, atrial fibrillation,
ender, creatinine, severity of tricuspid regurgitation, chronic
ioverter-defibrillator, LV ejection fraction, inotrope, history
c dimension.
terval; HR  hazard ratio; LV  left ventricular; otheron M
ssist
H
0.6
0.5
1.0
2.7
1.8
1.6
0.9
0.9
t covar
male g
le card
iastoliigure 1. Event-free survival for non-mitral-valve annuloplasty (MVA)
roup (solid line) and MVA group (dotted line).
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Mitral Valve Annuloplasty for MR and LV Dysfunction February 1, 2005:381–7rtery disease—would be expected to be associated with
etter prognosis. Older age has been shown to be associated
ith poorer survival after mitral valve replacement (19), and
ay have contributed to worse outcomes after MVA, but in
ur analysis, age was not associated with mortality, LV assist
evice implantation, or UNOS status 1 transplantation.
oronary disease was found to be an independent predictor
f mortality in this study and represents a key difference in
he MVA and non-MVA subjects. After exclusion of
atients with coronary disease from the analysis, however,
he conclusion regarding the lack of association between
itral surgery and clinical outcomes does not change. The
ther differences in baseline characteristics would be ex-
ected to make prognosis appear worse in the non-MVA
roup. The presence of lower LV ejection fraction and
igher heart rate has been shown to be associated with poor
rognosis in HF (20,21).
The surgically and medically treated groups also differed
ith respect to defibrillator use and spironolactone use.
lthough each of these therapies has been shown to reduce
ortality in patients with systolic heart failure (22–24),
either of these variables was associated with improved
urvival in our analysis. As these treatments are more likely
o be applied to patients with more severe disease, in a
etrospective analysis the perceived impact on mortality risk
ay be diminished. We repeated the multivariable analysis
orcing each of these variables into the model and found no
hange in the predictive value of the MVA time-dependent
ovariate.
In our multivariable analysis, many of the predictors of
linical outcome (coronary artery disease, serum sodium,
lood urea nitrogen, beta-blocker therapy, mean arterial
ressure, and ACE inhibitor therapy) are consistent with
hose factors previously established to have prognostic
mportance in HF in general. Indicative of an activated
igure 2. Event-free survival for patients without coronary artery disease in
on-mitral-valve annuloplasty (MVA) group (solid line) and MVA group
dotted line).enin-angiotensin-aldosterone system, low serum sodium eas clearly established as a prognostic indicator in heart
ailure more than 20 years ago and remains an important
arker of disease severity (25). Serum sodium, presence of
oronary artery disease, mean arterial pressure, and QRS
nterval are components of the Heart Failure Survival Score,
multivariable model used to risk stratify ambulatory
atients with heart failure (21). The adjusted HRs we
btained for these variables are remarkably similar to those
btained for the Heart Failure Survival Score. Beta-blocker
herapy clearly improves mortality in chronic heart failure.
ecent meta-analyses have also shown that beta-blocker
herapy for heart failure reduces all-cause mortality, cardio-
ascular mortality, and mortality due to pump failure and
udden death by roughly 31% to 39% (26,27). Consistent
ith these findings, we found a protective adjusted hazard
atio of 0.59 (95% CI 0.42 to 0.83) imparted by beta-
locker therapy. Our finding that a history of cancer was
ssociated with greater risk of adverse outcome was not
urprising, given the increased mortality associated with
ancer.
tudy limitations. The data presented in this study repre-
ent our clinical experience with a consecutive series of
atients with MR and severe LV systolic dysfunction rather
han a prospective randomized clinical trial. The adverse
utcomes assessed in this population of patients may be
nfluenced by factors that could not be assessed in our review
f the data (i.e., functional status). Given the complex
ecision making involved in the determination of surgical
andidacy, it is critical that preexisting influences of comor-
idities on clinical outcomes be considered. Not measured
n our study are the factors that make a patient willing to
gree to surgery. We cannot comment on whether these
nmeasured factors either made the MVA group higher risk
t baseline, the medical group lower risk at baseline, or both,
nd whether MVA improved clinical outcomes to a degree
omparable to that of the medical group. Given the different
utcomes of clinical series versus randomized controlled
rials, the influence of unmeasured confounding factors is
mportant to consider. The results of the study should be
aken in the context of the relatively small sample size
ncluded in the analysis, particularly in the noncoronary
isease cohort.
There is potential for lead-time bias in this retrospective
nalysis. We do not know the initial time of diagnosis for each
atient. It is possible that patients with severe MR and LV
ystolic dysfunction referred for surgery from outside the
niversity of Michigan Health System had significant unac-
ounted survival time before undergoing echocardiography in
ur clinics or hospital. Candidates for MVA who did not
ndergo MVA were followed for a longer time period in the
niversity of Michigan Health System before the index echo-
ardiogram compared with candidates who did undergo
VA. We attempted to examine the issue of lead-time bias by
omparing whether the patient was hospitalized at the time of
chocardiography. There were no differences in the proportion
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ram in the MVA or no-MVA groups.
This study analyzes clinical outcomes of patients with
reatment initiating from the years 1995 to 2002. Changes
n medical treatment and surgical techniques may have
mproved over this time period, leading to lower mortality
ates. Similarly, changes in surgical techniques (i.e., use of
igid, rather than flexible, mitral annuloplasty rings) may
ead to a more durable repair and lessen the chance of
esidual MR postoperatively. Changes in other aspects of
erioperative and postoperative medical care of the surgi-
ally treated patients may also lead to improved clinical
utcomes in more recently treated patients. Furthermore,
hese data do not include routine postoperative echocardio-
raphic assessment to determine the influence of residual
R on subsequent long-term outcomes.
onclusions. Despite previous evidence demonstrating
emodynamic and symptomatic improvement with good
ntermediate-term outcomes, and current low surgical mor-
ality, retrospective analysis of this large cohort of patients
ith LV dysfunction and significant MR demonstrates no
ortality benefit conferred by undergoing MVA. Prognosis
n this group of patients is associated with several clinical
actors that have been shown previously to be predictive in
F patients in general, whereas undergoing MVA was not
ssociated with the combined end point of death, LV assist
evice implantation, or UNOS status 1 heart transplanta-
ion. Further study with a prospective randomized control
rial will be needed to clarify which HF patients will benefit
rom MVA.
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